Substituted tricyclic heterocyclic compounds

US10189840B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Hai-Yun Xiao · Montgomery, US
• Murali T. G. Dhar · Newtown, US
• Jingwu Duan · Yardley, US
• Bin Jiang · Norristown, US
• Andrew J. Tebben · New Hope, US

Key dates

• Filing date: Mar 17, 2016
• Grant date: Jan 29, 2019
• Expiry date: Mar 17, 2036

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D487/06
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Disclosed are compounds of Formula (I) or a salt thereof, wherein: X is N; W is: (i) —(CR3R3)1-4—; (ii) —(CR3R3)x—Y—(CR3R3)y—; Or (iii) —Y—(CR3R3)2—Y—; and Y, R1, R2, R3, R5, R6, R8, x, and y are defined herein. Also disclosed are methods of using such compounds as modulators of TNFα, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating inflammatory and autoimmune diseases.